Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628692 · ClinicalTrials.gov registry record · Phase 2
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT01628692 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 230 participants.
The verdict
NCT01628692, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Simeprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01628692
The ClinicalTrials.gov registry entry for NCT01628692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01628692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01628692 about?
NCT01628692 is a clinical study titled "Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus". The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.
What is the current status of trial NCT01628692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2012-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01628692?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Simeprevir (DRUG).
Who is sponsoring clinical trial NCT01628692?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.